24.10.2021, 3552 Zeichen

Valneva: Valneva SE, a specialty vaccine company, today announced positive topline results from the Phase 3 pivotal trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The pivotal Phase 3, Cov-Compare trial recruited a total of 4,012 participants aged 18 years and older across 26 trial sites in the United Kingdom. The trial met its co-primary endpoints: VLA2001 demonstrated superiority against AZD1222 (ChAdOx1-S), in terms of geometric mean titer for neutralization antibodies (GMT ratio=1.39, p<0.0001), (VLA2001 GMT 803.5 (95% CI: 748.48, 862.59)),(AZD1222(ChAdOx1-S) GMT 576.6 (95% CI 543.6, 611.7)), as well as non-inferiority in terms of seroconversion rates (SCR above 95% in both treatment groups) at two weeks after the second vaccination (i.e. Day 43) in adults aged 30 years and older. T-cell responses analyzed in a sub-set of participants showed that VLA2001 induced broad antigen-specific IFN-gamma producing T-cells reactive against the S- (74.3%), N- (45.9%) and M- (20.3%) protein. VLA2001 was generally well tolerated. Thomas Lingelbach, Chief Executive Officer of Valneva, said: “These results confirm the advantages often associated with inactivated whole virus vaccines. We are committed to bringing our differentiated vaccine candidate to licensure as quickly as possible and continue to believe that we will be able to make an important contribution to the global fight against the COVID-19 pandemic. We are keen to propose an alternative vaccine solution for people who have not yet been vaccinated.”
Valneva: weekly performance: 57.67%

Atrium: Atrium European Real Estate Limite, a leading owner, operator and redeveloper of shopping centres and retail real estate in Central Europe, announces that the Independent Committee of the Board of Directors of Atrium and the board of directors of Gazit Hercules 2020 Limited, which is an indirect wholly-owned subsidiary of Gazit-Globe, have signed a definitive merger agreement for a recommended cash acquisition of the entire issued and to be issued ordinary share capital of Atrium that is not already owned directly or indirectly by Gazit or its affiliates for cash at a price of Euro 3.63 per Atrium share (the "Offer Price"), including a payment in the amount of Euro 3.03 per share in cash paid by Gazit and Euro 0.60 per share by way of a cash dividend paid by the Company. In addition to the increase of the Offer Price, the Independent Committee has also negotiated that Atrium shareholders are entitled to receive the pro-rata funds from operations less maintenance capital expenditure generated between the date of the last dividend payment and completion of the Acquisition (the "AFFO"). Shareholders will receive both the Offer Price and the AFFO. The shares of the Company are currently listed and admitted to trading on the Amsterdam Stock Exchange and the Vienna Stock Exchange and will be delisted from both stock exchanges after the effective date of the Merger.
Atrium: weekly performance: 11.32%

Andritz: International technology group Andritz has successfully started up the tissue production line delivered to Xuong Giang Paper Mill, Vietnam, a subsidiary company of Bac Giang Import Export JSC. The PrimeLineCOMPACT S 1300 tissue machine has a design speed of 1,300 m/min and a paper width of 2.85 m, processing virgin pulp as raw material to produce high-quality facial and toilet tissue as well as napkins.
Andritz: weekly performance: 1.74%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/10/2021)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S12/08: Robert Abend

Bildnachweis

Aktien auf dem Radar:Amag, Palfinger, SBO, Addiko Bank, Flughafen Wien, Austriacard Holdings AG, EVN, EuroTeleSites AG, Pierer Mobility, Semperit, Bawag, Kostad, Wolford, Oberbank AG Stamm, Polytec Group, ams-Osram, Agrana, CA Immo, Erste Group, Immofinanz, Kapsch TrafficCom, Mayr-Melnhof, OMV, Österreichische Post, Strabag, Telekom Austria, Uniqa, VIG, Wienerberger, Covestro, Sartorius.

---